# Rich Small

> Rich Small is the CEO of Neurotech Pharmaceuticals, the Cumberland, Rhode Island clinical-stage biotech that in March 2025 won FDA approval for ENCELTO, the first and only treatment for macular telangiectasia type 2 (MacTel). A CPA and Northeastern University graduate, he joined Neurotech as CFO in 2007 and took over the top job in 2016, guiding the company's encapsulated cell technology platform from experimental science to a commercial retinal implant.

- **Role:** Chief Executive Officer at Neurotech Pharmaceuticals, Inc.
- **Organizations:** Neurotech Pharmaceuticals, Inc., New England College of Optometry (former Trustee), Point Therapeutics (former), Immulogic Pharmaceutical (former), Dennison Manufacturing (former), Coopers & Lybrand (former)
- **Nationality:** American
- **Education:** BSBA, Accounting, Northeastern University
- **Known for:** Led Neurotech to FDA approval of ENCELTO (revakinagene taroretcel-lwey), the first and only approved treatment for MacTel., Helped shift FDA thinking toward structural endpoints for slow-progressing retinal diseases., Guided commercialization of the encapsulated cell technology (ECT) platform.

## Career timeline

- **1977** — Graduated Northeastern University with BSBA in Accounting; began career at Coopers & Lybrand.
- **1980s** — Senior financial and treasury roles at Dennison Manufacturing Company.
- **1990s** — VP and CFO at Immulogic Pharmaceutical, Inc.
- **1995** — Elected Trustee, New England College of Optometry.
- **2000s** — SVP and CFO at Point Therapeutics; helped take company public.
- **2007** — Joined Neurotech Pharmaceuticals as CFO.
- **2016** — Named President and CEO of Neurotech Pharmaceuticals.
- **2022** — Concluded 27-year tenure as NECO Trustee.
- **2025** — FDA approves ENCELTO for macular telangiectasia type 2.

## Achievements

- Led Neurotech to FDA approval of ENCELTO (revakinagene taroretcel-lwey), the first and only approved treatment for MacTel.
- Helped shift FDA thinking toward structural endpoints for slow-progressing retinal diseases.
- Guided commercialization of the encapsulated cell technology (ECT) platform.
- Served 27 years as Trustee of the New England College of Optometry, chairing Finance and Business Affairs.

## Latest updates

- **2025-03** — FDA approved ENCELTO for macular telangiectasia type 2.
- **2026-03** — Neurotech issued a corporate update on ENCELTO commercial progress.

## Links

- Website: https://neurotechpharmaceuticals.com
- LinkedIn: https://www.linkedin.com/in/rich-small-92a91032/
- Twitter/X: https://twitter.com/NeurotechPharma

---

Profile page: https://yespress.io/rich-small
Published by YesPress — https://yespress.io
Last updated: 2026-07-08